Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 14.13% is 22% below its 5-year average of 18.07%, near the low end of its 5-year range (12.85%–30.96%).
As of the fiscal period ended Wednesday, December 31, 2025. 5.88% above its 12-month average of 13.34%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
14.13%
RETURN ON EQUITY (ROE) AVG TTM
13.34%
RETURN ON EQUITY (ROE) AVG 3Y
14.07%
RETURN ON EQUITY (ROE) AVG 5Y
18.07%
RETURN ON EQUITY (ROE) AVG 10Y
16.59%
RETURN ON EQUITY (ROE) AVG 15Y
14.40%
RETURN ON EQUITY (ROE) AVG 20Y
15.69%
CURRENT VS TTM AVG
+5.88%
CURRENT VS 3Y AVG
+0.43%
CURRENT VS 5Y AVG
-21.80%
CURRENT VS 10Y AVG
-14.83%
CURRENT VS 15Y AVG
-1.91%
CURRENT VS 20Y AVG
-9.93%
SECTOR MEDIAN · HEALTHCARE
12.09%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+16.87%
vs the sector median at left
Quest Diagnostics Incorporated
Market Cap
$26.22B
Return on Equity (ROE)
14.13%
TTM Avg
13.34%
3Y Avg
14.07%
5Y Avg
18.07%
Market Cap
$26.23B
Return on Equity (ROE)
11.65%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$25.06B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
Market Cap
$24.85B
Return on Equity (ROE)
25.41%
TTM Avg
12.92%
3Y Avg
11.29%
5Y Avg
9.83%
Market Cap
$28.44B
Return on Equity (ROE)
8.55%
TTM Avg
9.02%
3Y Avg
4.86%
5Y Avg
4.86%
Market Cap
$23.66B
Return on Equity (ROE)
-46.61%
TTM Avg
-32.64%
3Y Avg
-13.90%
5Y Avg
0.25%
Market Cap
$23.49B
Return on Equity (ROE)
-6.79%
TTM Avg
-4.55%
3Y Avg
10.63%
5Y Avg
21.70%
Market Cap
$29.04B
Return on Equity (ROE)
7062.40%
TTM Avg
-2178.82%
3Y Avg
-341.14%
5Y Avg
-117.12%
Market Cap
$29.23B
Return on Equity (ROE)
59.67%
TTM Avg
-187.43%
3Y Avg
134.89%
5Y Avg
51.69%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $26.22B | 14.13% | 13.34% | 14.07% | 18.07% |
| Labcorp Holdings Inc. (LH)vs › | $26.23B | 11.65% | 9.71% | 9.35% | 12.84% |
| West Pharmaceutical Services, Inc. (WST)vs › | $25.06B | 18.89% | 16.95% | 19.08% | 20.56% |
| Incyte Corporation (INCY)vs › | $24.85B | 25.41% | 12.92% | 11.29% | 9.83% |
| Medline Inc. (MDLN)vs › | $28.44B | 8.55% | 9.02% | 4.86% | 4.86% |
| Moderna, Inc. (MRNA)vs › | $23.66B | -46.61% | -32.64% | -13.90% | 0.25% |
| BioNTech SE (BNTX)vs › | $23.49B | -6.79% | -4.55% | 10.63% | 21.70% |
| Mettler-Toledo International Inc. (MTD)vs › | $29.04B | 7062.40% | -2178.82% | -341.14% | -117.12% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $29.23B | 59.67% | -187.43% | 134.89% | 51.69% |
| STERIS plc (STE)vs › | $23.03B | 8.38% | 10.12% | 7.00% | 7.00% |
ROE
14.1%
ROA
6.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 13.84% |
| 2024-12-31 | 12.85% |
| 2023-12-31 | 13.54% |
| 2022-12-31 | 16.05% |
| 2021-12-31 | 30.96% |
| 2020-12-31 | 21.17% |
| 2019-12-31 | 15.21% |
| 2018-12-31 | 14.11% |
| 2017-12-31 | 15.69% |
| 2016-12-31 | 13.94% |
| 2015-12-31 | 15.14% |
| 2014-12-31 | 12.93% |
| 2013-12-31 | 21.50% |
| 2012-12-31 | 13.35% |
| 2011-12-31 | 12.74% |
| 2010-12-31 | 17.87% |
| 2009-12-31 | 18.28% |
| 2008-12-31 | 16.13% |
| 2007-12-31 | 10.23% |
| 2006-12-31 | 19.42% |
| 2005-12-31 | 19.77% |
| 2004-12-31 | 21.81% |
| 2003-12-31 | 18.24% |
| 2002-12-31 | 18.21% |
| 2001-12-31 | 12.15% |
| 2000-12-31 | 9.89% |
| 1999-12-31 | -0.39% |
| 1998-12-31 | 4.74% |
| 1997-12-31 | -4.12% |
| 1996-12-31 | -116.19% |
